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Abstract: Alzheimer disease (AD) is one of the most common neurodegenerative diseases and the most prevalent form of dementia.
Some factors in the development of AD, age being the best-known one, have been suggested; however, no causes have been found
yet. The pathophysiology of the disease is highly complex, current therapies are palliative, and a cure is still lacking. Adverse effects of
anesthetics in the elderly have been reported since the 1950s; however, awareness of this old problem has recently gained importance
again. Whether exposure to surgery and general anesthesia (GA) is associated with the development of AD has been questioned. As
the population is aging, many elderly patients will need to be anesthetized, and maybe some were already anesthetized before they were
diagnosed. Exposure to anesthetics has been demonstrated to promote pathogenesis of AD in both in vitro and in vivo studies. However,
to date, there have not been any clinical trials to address a link between exposure to GA and the development of AD in humans.
Therefore, before making any conclusions we need further studies, but we should be aware of the potential risks and take cautions with
vulnerable elderly patients.
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1. What is Alzheimer disease? Definition, facts, cause or
risk factors, and pathophysiology
The Alzheimer’s Association defines Alzheimer disease
(AD) as an irreversible and progressive fatal brain disease
that causes problems with memory, thinking, and behavior.
AD is the most common cause of dementia, not a normal
part of aging with still unknown cause and cure. Because
of increased life expectancy, during the next 25 years the
number of people with AD in the United States is expected
to increase by about 40% more than the current prevalence,
just as the costs associated with AD will increase (1).
The disease develops as a result of multiple factors
such as advanced age, female sex, lower educational
status, family history, and specific genetic mutations. A
very small percentage of people with AD (less than 5%)
have the familial form. AD has still unknown genetic and
environmental risk factors contributing to its development.
The link between exposure to environmental chemical
agents and AD has been suspected, providing a potential
relation for the possible role of general anesthesia (GA)
in AD pathogenesis. With a substantial population being
affected by this disease, it is likely that not only neurologists
or psychiatrists but also all physicians including
anesthesiologists in the coming years will encounter many
patients with AD.
* Correspondence: inangozde@yahoo.com
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The pathogenesis of this disease is complex, involving
molecular, cellular, and physiological pathologies.
The pathological changes are similar to normal aging
qualitatively, but different quantitatively. Two major
protein abnormalities are mainly responsible in the
pathogenesis of the disease: β-amyloid peptides (Aβ
peptides) and tau. Aβ peptides are normal products of
metabolism, but an imbalance between production and
clearance occurs in AD and excess Aβ peptides aggregate as
extracellular plaques. Tau protein is normally responsible
for stabilization of microtubules and transportation of
vesicles. In AD, tau protein is hyperphosphorylated,
and this form causes abnormal microtubules and forms
intracellular neurofibrillary tangles (2). These two main
abnormalities contribute to neurotoxic processes including
oxidative stress, inflammation, failure of synaptic function,
depletion of neurotransmitters, and eventually cell death.
Finally, all together, they cause AD. Macroscopic changes
include global brain atrophy, ventricular enlargement, and
widening of sulci that are more prominent in frontal and
temporal lobes; subsequently, there is an overall shrinkage
of brain tissue (3).
Diagnosis of AD is still clinical or based on microscopic
examination of the brain on autopsy; however, several
diagnostic tests have been developed to help confirmation.
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It is well known that cerebrospinal fluid biomarkers are
characterized by an increase in total and phosphorylated
tau, but a decrease in Aβ. Advanced medical imaging with
computed tomography, magnetic resonance imaging,
single-photon emission computed tomography, or
positron emission tomography are recommended for
routine evaluation of AD and these imaging methods
help to exclude other cerebral pathologies or subtypes of
dementia.
2. AD and anesthesia
2.1. Postoperative cognitive functions
It has been suggested that an association among anesthesia,
surgery, delirium, postoperative cognitive dysfunction
(POCD), and dementia exists. Depending on the age of the
patient and the type of surgery, delirium is an extremely
common and distressing postoperative complication with
a prevalence of 10%–15% in elderly patients who receive
GA. POCD is also a common complication in the early
weeks following surgery and anesthesia. Whether POCD is
reversible or not is still unclear, and whether it is associated
with the anesthesia or surgery remains controversial. It is
particularly common following cardiac and orthopedic
procedures. POCD after anesthesia may represent the
cognitive decline that occurs in elderly people and is
known to precede the dementia of AD.
Bedford first reported postoperative confusion in
elderly patients as early as 1955. He reviewed 1193 patients
over 50 years old who had received GA and found that
10% of his patients had POCD; he suggested anesthetic
agents and hypotension to be probable causes of cognitive
dysfunction. He recommended that operations on elderly
patients be limited in terms of unnecessary procedures.
On that basis, the first International Study of Postoperative
Cognitive Dysfunction (ISPOCD) reported the next major
study of POCD in 1998 (4). In noncardiac patients of more
than 59 years old, the incidence of cognitive dysfunction
1 week after surgery was 22% higher and 3 months after
surgery was 7% higher than in age-matched controls.
Similar to Bedford’s finding, 10% of patients presented
with POCD. Increasing age, duration of anesthesia, lower
educational status, repetitive operations, postoperative
infection, and respiratory complications were reported
as risk factors for early POCD and only age remained
statistically significant during the 3-month follow-up
among the risk factors.
2.2. Is GA a risk factor for AD?
For a long time, it was assumed that most anesthetics have
neuroprotective effects. In particular, barbiturates, volatile
anesthetics, and propofol are known to inhibit ischemic
cascades by suppressing excitatory neurotransmitters and
potentiating inhibitory ones. However, recently doubt
about their neurotoxicity, especially at extreme ages

in neonates and the elderly, has been arising and new
evidence has suggested that they may be responsible for a
number of sequelae following exposure.
Preclinical evidence from animal models and in vitro
studies has suggested the potential relation between GA
and AD. Association between exposure to GA and the
development of AD has been shown in transgenic mouse
models (5), and Aβ peptide-related processes and tauopathy
have been observed in animals exposed to GA (6).
There is essentially a lack of evidence to suggest
anesthetics-induced neurotoxicity in humans. There have
been no randomized controlled clinical trials examining
the risk of AD associated with exposure to anesthesia.
The only randomized controlled trials were held based
on comparison of the effects of general versus regional
anesthesia on the risk of POCD (7). Nevertheless, to
provide evidence-based observational studies, casecontrol and cohort studies have gained importance. In
a recent report (8), epidemiological evidence for GA as
a risk factor for AD was reviewed. Methodologically,
the authors preferred to exclude cognitive outcomes
rather than dementia, such as delirium or POCD, and
no evidence was found that suggested any link between
exposure to GA and development of clinically diagnosed
dementia. The same group also published a metaanalysis
of 15 case-controlled studies that met their inclusion
criteria (9). None of the studies demonstrated a significant
increased risk of AD associated with GA individually;
they also failed to demonstrate any evidence of increased
risk of AD following previous exposure to GA compared
to no history of GA exposure in the metaanalysis. In a
recent population-based case-control study carried out
at the Mayo Clinic, it was concluded that receiving GAfor
procedures after the age of 45 years old was not a risk
factor for incident dementia (10).
However, some reviews suggested that exposure to
anesthetics would promote the risk of AD. In patients 80
years old or older, AD was found to be associated with
exposure to GA. Chen et al. (11) also showed a significantly
increased risk in development of dementia 3–7 years after
anesthesia and surgery.
There has been no prospective cohort study on this
topic. Similar to case-control studies, the results of the
limited number of retrospective cohort studies are also
unsettling. Lee et al. (12) compared the risk of developing
AD 5–6 years after coronary artery bypass graft (CABG)
surgery under inhalational anesthesia versus the risk
of developing AD within 5–6 years of percutaneous
transluminal coronary angioplasty (PTCA). In the CABG
patients, AD developed more often than in PTCA patients.
Vanderweyde et al. (13) evaluated the risk of AD following
exposure to GA compared to local anesthesia in two
surgical cohort studies on prostate and hernia surgeries.
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In that analysis, in contrast to previous findings, exposure
to GA was associated with a reduced risk of AD when
compared to local anesthesia.
Preclinical studies suggest that anesthetics may affect
cognition by mimicking the molecular mechanism in the
pathogenesis of AD (Figure).
In particular, effects of inhaled anesthetics share
two major pathologic abnormalities with AD. They
increase production and aggregation of Aβ peptides and
induce hyperphosphorylation and accumulation of tau.
Anesthetics facilitate disinhibition of protein binding and
thus help monomers to aggregate. If those monomers are
Aβ, this oligomerization results in neurotoxicity. Inhaled
anesthetics have also been demonstrated to increase the
formation of AD precursors in both in vivo models and in
vitro studies (14,15).
In 2004, Eckenhoff et al. (16) initiated neurotoxicity
studies and demonstrated that the inhalation anesthetics
isoflurane and halothane enhanced Aβ oligomerization
in vitro and potentiated Aβ-induced cytotoxicity in rat
pheochromocytoma cells. Xie et al. (14) studied the
effects of isoflurane on apoptosis and Aβ levels in human
neuroglioma cells and reported that treatment with 2%
isoflurane for 6 h induced caspase-3 activation, cell death,
and accumulation of extracellular levels of Aβ in the
cells. Despite these findings suggesting that isoflurane is
neurotoxic, there have been many reports that suggest that
isoflurane may protect against neurotoxicity. Isoflurane’s
protection effects have been shown to be dual, both doseand time-dependent (17).

When compared with isoflurane, halothane led to more
amyloid deposition in transgenic mice than isoflurane.
Sevoflurane was also associated with increases in Aβ
in mouse models (18). Desflurane, a newer inhalation
anesthetic, different from isoflurane and sevoflurane, was
shown to have no effect on caspase-3 activation, APP
processing, and Aβ accumulation in human neuroglioma
cells and does not induce learning and memory
impairments in mice (19). Similar to desflurane, Zhen et al.
(20) showed that nitrous oxide did not cause apoptosis or
Aβ accumulation in cells and neurons. In summary, these
findings suggest that nitrous oxide and desflurane have
preferable features in regards to their effect on Aβ protein
as compared to the other commonly used inhalation
anesthetics, isoflurane and sevoflurane (6).
Palotas et al. first investigated the effect of propofol
on Aβ protein (21). They studied the effects of propofol
on the precursor protein of Aβ (APP) in rats and found
that propofol does not affect APP. Moreover, propofol was
found to inhibit isoflurane-induced Aβ42 oligomerization
(22). These data may suggest that propofol does not
promote Aβ pathology.
Molecular size of the anesthetic seems to be
the significant contributing factor in inducing Aβ
oligomerization. Magnetic resonance imaging studies
suggest that smaller-sized agents like volatile anesthetics
can promote Aβ oligomerization whereas larger-sized
intravenous agents cannot interact with Aβ protein and do
not promote Aβ oligomerization (halothane > isoflurane >
sevoflurane > propofol > thiopental > diazepam) (23).
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Figure. Schema of how anesthesia causes AD.
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Both preclinical and early clinical studies suggest
that anesthetics can accelerate tau pathology by inducing
massive and rapid hyperphosphorylation of tau. This
effect may be independent of the anesthetic used,
but the presence of hypothermia during anesthesia, a
common clinical occurrence, appears to exacerbate the
degree of phosphorylation. Furthermore, reestablishing
normothermia during anesthesia was shown to restore tau
phosphorylation to normal levels (15).
However, anesthesia-induced hypothermia appears
to not be the only reason for the development of
tauopathy, since tau phosphorylation has been reported
in normothermic conditions. This second mechanism
represents a direct way, independent of hypothermia,
and involves stress-activated protein kinase activation.
Whittington et al. (24) suggested that hypothermia, which
is common in the elderly, might enhance AD pathology.
The same group investigated the effect of propofol on tau
phosphorylation under normothermic conditions and
found that hyperphosphorylation still occurred in the
absence of hypothermia. Subsequently, they examined
the impact of dexmedetomidine and found similar tau
hyperphosphorylation under normothermic conditions.
With a further study, Le Freche et al. (25) observed that acute
exposure to the inhalational anesthetic sevoflurane resulted
in significant dose-dependent tau hyperphosphorylation
in the hippocampus of nontransgenic mice under
normothermic conditions and suggested that this is not
specific even for intravenous anesthetics. Nevertheless,
the impact of anesthesia with hypothermia or not on tau
pathology should not be underestimated as the number of
patients having surgery increases steadily.
2.3. Surgery, neuroinflammation, and AD
Relations between surgery, anesthesia, AD, and
neuroinflammation have been studied. Much of the
evidence has derived from animal studies; human studies
on this topic are rare. It appears that neuroinflammation
plays an important part in the neuropathogenesis of
neurodegenerative disorders like AD. Both surgery
and anesthesia produce neuroinflammation to some
degree separately. Surgery initially causes a peripheral
inflammation response and as this inflammation
is transferred to the central nervous system (CNS)
depending on neurohumoral factors and encountering the
blood/brain barrier, a systemic inflammatory response is
produced. The mechanism of the way in which surgery
impairs cognition is not yet clear, but possibly stressinduced hormonal responses, inflammatory cascades,
and circulatory, respiratory, and temperature instability
due to surgery are involved. The role of surgery-induced
inflammation in POCD is enhanced by age (26).
Anesthesia has both antiinflammatory and
proinflammatory effects. However, anesthetics are

supposed to have neuroinflammatory effects depending on
the drug and dose administered. Intravenous agents such
as propofol and ketamine do not cause neuroinflammation,
whereas with volatile anesthetics, and especially with
isoflurane, neuroinflammation was noted.
Nevertheless, anesthesia and surgery have been rarely
administered separately to allocate their impairment on
postoperative cognition. It is difficult to say that surgery
or anesthesia alone is the cause of postoperative decline,
and it is certain that surgery and anesthesia together
potentiate each other’s effect and lead to a steeper decline
in cognitive functions. In vulnerable patients, such as the
elderly or possible AD patients, it appears that anesthesia
and surgery would promote neuroinflammation and AD
pathogenesis.
2.4. Do anesthetic techniques differ in the risk of AD?
Most reviews indicated that there was limited evidence to
suggest any difference between GA and regional anesthesia
for the risk of POCD (27–29).
Absence of further evidence to suggest any difference
between GA and regional anesthesia on the incidence of
POCD can be explained by the use of intravenous sedation
with regional anesthesia that may increase the risk and
negate the difference.
Nevertheless, Wu et al. (27) failed to show a
difference between different anesthesia techniques on
the development of POCD in their systematic review. In
a clinical update (29), GA was compared with regional
anesthesia for their influences on delirium or POCD. A
total of 18 randomized controlled trials were identified, 2
evaluating delirium, 10 evaluating POCD, and 6 evaluating
both; no significant difference was found.
On the contrary, a review of anesthesia for hip fracture
surgery found a reduction in acute postoperative confusion
with regional anesthesia compared to GA (30). However,
the authors concluded that the evidence from the trials was
not sufficient enough to rule out any clinically important
conclusions. Mason et al. (28) in their systematic review
with metaanalysis compared the influence of general,
regional, or combination anesthesia on the development
of POCD and postoperative delirium (POD). They found
an increase in the incidence of POCD but not POD with
GA. Vanderweyde et al. (13) compared effects of GA and
local anesthesia on the risk of developing AD in patients
undergoing either prostate or hernia surgery. Exposure to
GA did not increase the risk of AD, and interestingly it was
associated with a reduced risk of AD when compared to
local anesthesia.
However, randomized controlled trials comparing
different anesthetic techniques found little or no difference
in long-term follow-up for persistent POCD following
exposure to GA when compared to regional anesthesia
(31).
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If GA is mandatory in the case of a possible regional
anesthesia contraindication or due to necessity of surgical
procedure, then a decision for maintaining anesthesia
with intravenous or inhalation anesthetics should be
made. Inhalational anesthesia has been associated with
higher risk of cognitive impairment in both in vivo and
in vitro studies. However, currently there are not enough
clinical studies to prove that inhalational anesthesia causes
dementia or AD in humans.
The inhalation anesthetic isoflurane has been shown to
induce caspase activation and increase Aβ accumulation,
which are associated with the key pathological pathways
in AD. In contrast, propofol has been reported to have
neuroprotective effects. Zhang et al. (22) compared
the effects of isoflurane and propofol individually and
in combination on Aβ oligomerization in vitro and in
vivo. Isoflurane alone induced Aβ42 oligomerization,
whereas propofol inhibited the isoflurane-mediated
oligomerization of Aβ42. Propofol would be a better
choice of anesthetic especially in vulnerable elderly and
AD patients.
3. Anesthetic considerations in patients with or at risk
of AD
Anesthetic management in elderly patients requires
appropriate preoperative evaluation, maintenance of
hemodynamic stability, and awareness of impairment
of circulatory and other systems by aging. Proper
preoperative consultation and information about such
potentials can be helpful to reduce the patient’s and the
family members’ anxiety.
Preoperative clinical assessment requires not only
physical status evaluation but also evaluation of cognitive
reserve. Performing a preoperative careful cognitive
evaluation using the Mini Mental State Exam (MMSE),
for example, before and after exposure to anesthesia may
be mandatory for all elderly patients undergoing general
anesthesia.
Biomarkers of the disease may be present many years
before clinical symptoms become apparent. CSF analysis of
tau and Aβ proteins is an important part of AD screening.
Xie et al. (32) studied the association of the AD biomarker
with changes in cognitive functions after elective surgery
and, consistent with previous findings, they found that the
presence of the AD biomarker preoperatively, specifically
the Aβ/tau ratio, may help to predict patients at higher
risk for cognitive changes after surgery. Silbert et al. (33)
suggested that anesthesiologists can play a key role in CSF
sampling, as they are skilled in lumbar puncture for spinal
anesthesia during routine anesthesia practice. However,
some ethical and moral issues, including informed consent
for CSF sampling and analysis, should be considered. Even
the biomarkers can show the presence of AD before the
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onset of symptoms, at present a cure is not available, and
some patients would prefer not to learn the results. Similar
ethical concerns are valid for genetic identification.
Particular precautions taken by the anesthesia and
surgical teams can prevent intra- and postoperative
complications and thereby reduce the risk of postoperative
cognitive decline (Table). Decisions can be made regarding
the extent of the procedure considering risks versus benefit,
or even whether an elective procedure should be canceled.
Surgeons must use meticulous surgical techniques,
minimally invasive if possible.
Age-related systemic impairments, malnutrition, poor
hygiene, incontinence, and chronic diseases may be present
in patients with or at risk of AD at the time of surgery.
Anesthesiologists must carefully review the patient’s
medical history, evaluate systemic functions, and check
the prescribed and unprescribed medications considering
possible drug interactions. Attention should be paid to
preoperative sedation, especially with benzodiazepines,
because it may worsen postoperative mental confusion.
Dressler et al. (34) demonstrated memory impairment
in patients premedicated with midazolam on the first
postoperative day.
Although far from being clinically proven, there may
be a benefit to avoiding or decreasing inhaled anesthetic
exposure if possible in the AD patient.
It is essential to provide a tight intraoperative
homeostasis and keep the patient’s fluid, electrolyte,
oxygen, and glycemic balances to reduce cognitive
impairment. Studies show that achieving normoglycemia
during the intraoperative period improves postoperative
cognition. Both hypoglycemia and hyperglycemia should
be avoided.
Anesthesia-induced hypothermia is known to
cause tau hyperphosphorylation and could be reversed
if normothermia is sustained (35). Thus, monitoring
temperature and maintaining normothermia are
mandatory.
Fast-track anesthesia techniques seem to reduce
postoperative cognitive impairment and enable the patient
to cooperate earlier in the postoperative period. For this
reason, shorter-acting and rapidly eliminated anesthetic
drugs would improve early postoperative cognitive
recovery and reduce cognitive complications and
confusion in elderly patients. However, benzodiazepines
have been found to impair memory in the postoperative
period and sedation with benzodiazepines is not favored.
As delirium can accelerate postoperative cognitive decline,
it is important to decrease risk factors for POD. Cholinergic
deficiency plays a role in delirium and administration of
anticholinergic drugs can lead to delirium. To reduce the
risk of POD in elderly patients, physostigmine, reversible
cholinesterase inhibitors, and prophylactic use of
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Table. Anesthetic management of patients with AD

Preoperative evaluation

Preoperative assessment
Comorbid diseases
Prescribed medication
Family history
Previous surgeries
Habits: Alcohol, cigarettes, eating, sleeping
Informed consent
Early diagnosis
CSF sampling?
Ethical concerns
Cognitive evaluation - MMSE

Perioperative management

Monitoring
Glycemic balance, temperature, depth of anesthesia
Anesthetic technique
Cautious use of sedatives - avoid benzodiazepines
Decrease inhaled anesthetic exposure
Regional anesthesia?
TIVA?
Shorter-acting and more rapidly eliminated anesthetics
Reduce risk of POD
Avoid atropine
Use prophylactic neuroleptics
Prescribed cholinesterase inhibitors
Aware of increased cholinergic activity
Avoid succinylcholine
Prefer short acting NMBA
Spontaneous recovery of NM blockade
Sugammadex?

Postoperative interventions

Early extubation
Effective analgesia and if necessary sedation
Avoid benzodiazepines
Education and support

neuroleptics like haloperidol are advantageous treatment
strategies. Zhang et al. (36) in their metaanalysis suggested
sedation with dexmedetomidine and antipsychotics for
prevention of POD.
Commonly, patients with AD are prescribed
cholinesterase inhibitors to increase cholinergic
neurotransmitter activity in the CNS; however, the side
effects are not limited to the CNS. Cholinesterase inhibitors
may increase the duration of action of succinylcholine and
predispose patients to bradycardia. Theoretical concerns
with increased cholinergic activity also include risk of
ulcers, urinary incontinence, seizures, and obstructive
lung disease exacerbations.
Reducing the volatile agent exposure by monitoring
anesthetic depth has also been questioned; however, study
findings are inconsistent and an assessment of this issue is
not yet possible. A recent randomized controlled trial (37)
showed that keeping the depth level of anesthesia with BIS

between 40 and 60 was associated with a lower incidence
of POCD and delirium at 3 months postoperatively.
4. Conclusion
It is very difficult to draw any conclusions about the
anesthetic agents to be used or avoided in patients with AD.
Further comprehensive research is required to review the
anesthesia protocols so as to limit the impact of anesthesia
on patients with or at risk of AD. At the present time, there
is no evidence to support an association between exposure
to GA and increased risk of AD based on available clinical
data. The existing literature is insufficient due to a lack of
human studies. However, we cannot ignore evidence from
both in vivo and in vitro studies indicating potential risks.
Elderly patients and their families should be warned about
the possibility of postoperative cognitive decline and efforts
should be made to optimize the perioperative care of older
patients. Using human biomarkers and neuroimaging
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modalities might gain importance in the future or lead
new discussions on ethical issues. The decision of which
anesthetics to choose should be made on the basis of the
surgical procedure and other factors related to the patient.
There is a strong need for adequately powered, longterm, prospective cohort studies or randomized controlled

trials or retrospective studies for further understanding
the association between anesthesia and the risk of AD
in humans after surgery. The expanding life expectancy
indicates consideration of this issue since we might be the
ones who relying on these improvements one day.
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